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of busulfan pharmacokinetics. In conjunction with sparse sampling, 
the proposed model-based dosing algorithm appears to ensure that 
patients achieve and maintain the expected target exposure.
Conclusion: In contrast to the current clinical protocol, which relies 
on a linear correlation between dose and body weight, our findings 
reveal the clinical implications of a nonlinear correlation between 
body size, liver function, and drug elimination. The definition of the 
sparse ideal optimal design for busulfan constitutes an important 
improvement in therapeutic drug monitoring routine. Moreover, the 
availability of a model-based dosing algorithm for dose individu-
alization may contribute to considerable improvement in the safety 
and efficacy profile of patients undergoing treatment for stem cell 
transplantation.
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Introduction: In present scenario, India becomes a hub for con-
ducting clinical trials. Hence, need good clinical practice (GCP) to 
conduct a clinical trial. Initiative of Indian government of clinical 
trial registry (CTRI) has helped in increasing transparency, account-
ability, and accessibility of clinical trials. We conducted retrospective 
observational study aimed to establish current Indian status of Good 
Clinical Practice certified clinical investigators in major government 
hospitals, private hospitals, and small polyclinic.
Patients (or Materials) and Methods: We have done extensive search 
of clinical trials registry in India to obtain information regarding the 
total number of trials registered and further divided into the sites 
specific like major government hospitals, private hospitals, and small 
polyclinic from year 2007 to 2012.
Results: Our paper is first of a kind to demonstrate the sites preferred 
by sponsor or investigator for conducting clinical trials. Looking into 
the data, it was found private institutes were preferred compared 
with government institutes and increasing number of trials were also 
conducted in polyclinics. Trends toward allocating of private institute 
though increased by 2011 but by 2012, both government and private 
institutes were equally allocated for clinical trials but decrease in 
registration of trials is noticed by the 2012. Proper coordination and 
timely completion of trial should be aimed at properly trained, quali-
fied, and experienced staff (GCP trained) with standard laboratories 
and regular monitoring.
Conclusion: Present study showed the importance and differences 
of site specific application of GCP objectives. The principle of GCP 
should be followed regardless of site and then expect a good clinical 
outcome and training during the study.
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Introduction: This study (in vivo) was performed to investigate so-
called “drift” with generic–generic drug substitution, namely whether 
a registered generic formulation is also bioequivalent to another 
generic formulation, fulfilling the 80% to 125% criterion.
Patients (or Materials) and Methods: This bioequivalence study was 
conducted at Maastricht University Medical Centre, and designed as 
a 800-mg tablet, single-dose, 4-treatment (Neurontin® and 3 regis-
tered generic gabapentin products), randomized, 4-way crossover 
trial in 24 healthy volunteers under fasting conditions.
Results: Six comparisons were performed among the 4 treatments 
to investigate the bioequivalence of different gabapentin formula-
tions. In all comparisons, the 90% CIs for the reference/test ratio 
of Cmax, AUCt, and AUCinf were within the routine 80.00% to 
125.00% criterion. The safety and tolerability profiles were com-
parable.
Conclusion: In this comparative bioavailability study, all 3 generic 
formulations of gabapentin were found to be interchangeable with 
Neurontin® and were also shown to be bioequivalent to each 
other. These results indicate the absence of a “drifting” problem 
upon gabapentin generic–generic exchange. Our study results are 
in line with those obtained from a previously conducted simulation 
study with topiramate and gabapentin based on bioequivalence data 
present in the registration files of the Dutch Medicines Evaluation 
Board1. Compared with the simulation study for generic-generic 
interchange, the ratios in the currently reported comparative bio-
availability study are comparable, albeit with narrower 90% CIs 
for Cmax and AUCt.
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Introduction: Landmark clinical trials have led to optimal treatment 
recommendations for patients with diabetes. However, whether opti-
mal treatment is actually delivered in practice is more important than 
the efficacy of the drugs tested in trials. To this end, treatment qual-
ity indicators have been developed and tested against intermediate 
outcomes of cardiovascular complications. No studies have tested 
whether these treatment quality indicators also predict hard patient 
outcomes.
Patients (or Materials) and Methods: Data were collected from 
10,058 patients with diabetes in the Groningen Initiative to Analyze 
Type 2 Treatment (GIANTT) database and Dutch Hospital Data 
register. Included quality indicators measured glucose, lipid, blood 
pressure, and albuminuria-lowering treatment status and treatment 
intensification when indicated. Hard patient outcome was the com-
posite of cardiovascular events and all-cause death. Associations 
